HIV-1 inactivation by nucleic acid aptamers

Frontiers in Bioscience

Volumn 11, Issue 1 P.1-446, 2006, Pages 89-112

  Held, Daniel M ^a,b   Kissel, Jay D ^a   Patterson, James T ^a   Nickens, David G ^a   Burke, Donald H ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b University of Missouri   (United States)

Author keywords

AIDS; gp120; HIV; Immune Deficiency; Matrix; Nucleocapsid; p55Gag; Rev; Review; RRE; TAR; Tat; Viral Entry; Viral expression; Viral Packaging; Virus

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 32844463163     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1782     Document Type: Review

References (192)

1. Dorman, N. & A. M. Lever: RNA-based gene therapy for HIV infection. HIV Med 2, 114-22 (2001)
2. Arenz, C. & U. Schepers: RNA interference: from an ancient mechanism to a state of the art therapeutic application? Naturwissenschaften 90, 345-59 (2003)
3. Sullenger, B. A. & E. Gilboa: Emerging clinical applications of RNA. Nature 418, 252-8 (2002)
4. Joshi, P. J., T. S. Fisher & V. R. Prasad: Anti-HIV inhibitors based on nucleic acids: emergence of aptamers as potent antivirals. Curr Drug Targets Infect Disord 3, 383-400 (2003)
5. Wang, Q. C., Q. H. Nie & Z. H. Feng: RNA interference: Antiviral weapon and beyond. World J Gastroenterol 9, 1657-61 (2003)
6. Tuerk, C. & L. Gold: Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 249, 505-10 (1990)
7. Ellington, A. D. & J. W. Szostak: In vitro selection of RNA molecules that bind specific ligands. Nature 346, 818-22 (1990)
8. Gold, L.: Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem. 270, 13581-4 (1995)
9. Pan, W., R. C. Craven, Q. Qiu, C. B. Wilson, J. W. Wills, S. Golovine & J. F. Wang: Isolation of virus-neutralizing RNAs from a large pool of random sequences. Proc. Natl. Acad. Sci. U S A 92, 11509-13 (1995)
10. Wilson, C. & J. W. Szostak: In vitro evolution of a self-alkylating ribozyme. Nature 374, 777-82 (1995)
11. Homann, M. & H. U. Goringer: Combinatorial selection of high affinity RNA ligands to live African trypanosomes. Nuc. Acids Res. 27, 2006-14 (1999)
12. Wang, J., H. Jiang & F. Liu: In vitro selection of novel RNA ligands that bind human cytomegalovirus and block viral infection. RNA 6, 571-83 (2000)
13. Hicke, B. J., C. Marion, Y. F. Chang, T. Gould, C. K. Lynott, D. Parma, P. G. Schmidt & S. Warren: Tenascin-C aptamers are generated using tumor cells and purified protein. J. Biol. Chem. 276, 48644-54 (2001)
14. Burke, D. H., L. Scates, K. Andrews & L. Gold: Bent pseudoknots and novel RNA inhibitors of type 1 human immunodeficiency virus (HIV-1) reverse transcriptase. J. Mol. Biol. 264, 650-66 (1996)
15. Tuerk, C., S. MacDougal & L. Gold: RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U S A, 89, 6988-92 (1992)
16. Eyetech, S. G.: Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 110, 979-86 (2003)
17. Fukuda, K., D. Vishnuvardhan, S. Sekiya, J. Hwang, N. Kakiuchi, K. Taira, K. Shimotohno, P. K. Kumar & S. Nishikawa: Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. Eur J Biochem 267, 3685-94 (2000)
18. Kumar, P. K., K. Machida, P. T. Urvil, N. Kakiuchi, D. Vishnuvardhan, K. Shimotohno, K. Taira & S. Nishikawa: Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 237, 270-82 (1997)
19. Nishikawa, F., N. Kakiuchi, K. Funaji, K. Fukuda, S. Sekiya & S. Nishikawa, Inhibition of HCV NS3 protease by RNA aptamers in cells. Nuc. Acids Res. 31, 1935-43 (2003)
20. Urvil, P. T., N. Kakiuchi, D. M. Zhou, K. Shimotohno, P. K. Kumar & S. Nishikawa, Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus. Eur J Biochem, 248, 130-8 (1997)
21. Jeon, S. H., B. Kayhan, T. Ben-Yedidia & R. Arnon, A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin. J. Biol. Chem. J. Biol. Chem. 279, 48410-9 (2004)
22. Burke, D. H. & D. G. Nickens: Expressing RNA aptamers inside cells to reveal proteome and ribonome function. Brief Funct Genomic Proteomic 1, 169-88 (2002)
23. Nickens, D. G., J. T. Patterson & D. H. Burke: Inhibition of HIV-1 reverse transcriptase by RNA aptamers in Escherichia coli. RNA 9, 1029-1033 (2003)
24. Good, P. D., A. J. Krikos, S. X. Li, E. Bertrand, N. S. Lee, L. Giver, A. Ellington, J. A. Zaia, J. J. Rossi & D. R. Engelke: Expression of small, therapeutic RNAs in human cell nuclei. Gene Ther. 4, 45-54 (1997)
25. Paul, C. P., P. D. Good, S. X. Li, A. Kleihauer, J. J. Rossi & D. R. Engelke: Localized expression of small RNA inhibitors in human cells. Mol Ther. 7, 237-47 (2003)
26. Thompson, J. D., D. F. Ayers, T. A. Malmstrom, T. L. McKenzie, L. Ganousis, B. M. Chowrira, L. Couture & D. T. Stinchcomb: Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nuc. Acids Res. 23, 2259-68 (1995)
27. Lin, Y. & S. D. Jayasena: Inhibition of multiple thermostable DNA polymerases by a heterodimeric aptamer. J. Mol. Biol. 271, 100-11 (1997)
28. Burke, D. H. & J. H. Willis: Recombination, RNA evolution, and bifunctional RNA molecules isolated through chimeric SELEX. RNA 4, 1165-75 (1998)
29. Lisziewicz, J., D. Sun, J. Smythe, P. Lusso, F. Lori, A. Louie, P. Markham, J. Rossi, M. Reitz & R. C. Gallo: Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc. Natl. Acad. Sci. U S A, 90, 8000-4 (1993)
30. Symensma, T. L., S. Baskerville, A. Yan & A. D. Ellington, Polyvalent Rev decoys act as artificial Rev-responsive elements. J. Virol., 73, 4341-9 (1999)
31. Joshi, P. & V. R. Prasad, Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment) J. Virol. 76 6545-57 (2002)
32. Green, L. S., D. Jellinek, C. Bell, L. A. Beebe, B. D. Feistner, S. C. Gill, F. M. Jucker & N. Janjic: Nuclease-resistant nucleic acid ligands to vascular permeability factor/vascular endothelial growth factor. Chem Biol., 2, 683-95 (1995)
33. Jellinek, D., L. S. Green, C. Bell, C. K. Lynott, N. Gill, C. Vargeese, G. Kirschenheuter, D. P. McGee, P. Abesinghe, W. A. Pieken, R. Shapiro, D. B. Rifkin, D. Moscatelli & N. Janjic: Potent 2′-amino-2′- deoxypyrimidine RNA inhibitors of basic fibroblast growth factor. Biochemistry 34, 11363-72 (1995)
34. Pagratis, N. C., C. Bell, Y. F. Chang, S. Jennings, T. Fitzwater, D. Jellinek & C. Dang: Potent 2′-amino-, and 2′-fluoro-2′- deoxyribonucleotide RNA inhibitors of keratinocyte growth factor. Nat. Biotechnol. 15, 68-73 (1995)
35. Micklefield, J., Backbone modification of nucleic acids: synthesis, structure and therapeutic applications. Curr Med. Chem, 8, 1157-79 (2001)
36. Williams, K. P., X. H. Liu, T. N. Schumacher, H. Y. Lin, D. A. Ausiello, P. S. Kim & D. P. Bartel: Bioactive and nuclease-resistant L-DNA ligand of vasopressin. Proc. Natl. Acad. Sci. U S A 94, 11285-90 (1997)
37. Wlotzka, B., S. Leva, B. Eschgfaller, J. Burmeister, F. Kleinjung, C. Kaduk, P. Muhn, H. Hess-Stumpp & S. Klussmann: In vivo properties of an anti-GnRH Spiegelmer: an example of an oligonucleotide-based therapeutic substance class. Proc. Natl. Acad. Sci. U S A 99, 8898-902 (2002)
38. Lorger, M., M. Engstler, M. Homann & H. U. Geringer: Targeting the variable surface of African trypanosomes with variant surface glycoprotein-specific, serum-stable RNA aptamers. Eukaryot Cell 2, 84-94 (2003)
39. Leva, S., A. Lichte, J. Burmeister, P. Muhn, B. Jahnke, D. Fesser, J. Erfurth, P. Burgstaller & S. Klussmann, GnRH binding RNA and DNA Spiegelmers: a novel approach toward GnRH antagonism. Chem Biol. 9, 351-9 (2002)
40. Schmidt, K. S., S. Borkowski, J. Kurreck, A. W. Stephens, R. Bald, M. Hecht, M. Friebe, L. Dinkelborg & V. A. Erdmann: Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nuc. Acids Res., 32, 5757-65 (2004)
41. Darfeuille, F., J. B. Hansen, H. Orum, C. Di Primo & J. J. Toulme: LNA/DNA chimeric oligomers mimic RNA aptamers targeted to the TAR RNA element of HIV-1. Nuc. Acids Res. 32, 3101-7 (2004)
42. Rump, E. T., R. L. de Vrueh, M. Manoharan, I. H. Waarlo, R. van Veghel, E. A. Biessen, T. J. van Berkel & M. K. Bijsterbosch: Modification of the plasma clearance and liver uptake of steroid ester-conjugated oligodeoxynucleotides by association with (lactosylated) low-density lipoprotein. Biochem Pharmacol, 59, 1407-16 (2000)
43. Bijsterbosch, M. K., M. Manoharan, R. Dorland, R. Van Veghel, E. A. Biessen & T. J. Van Berkel: bis-Cholesteryl-conjugated phosphorothioate oligodeoxynucleotides are highly selectively taken up by the liver. J Pharmacol Exp Ther 302, 619-26 (2002)
44. De Clercq, E.: New anti-HIV agents and targets. Med. Res. Rev. 22, 531-65 (2002)
45. De Clercq, E.: Antiviral drugs in current clinical use. J Clin Virol 30, 115-33 (2004).
46. Gulick, R. M.: New antiretroviral drugs. Clin Microbiol Infect. 9, 186-93 (2003)
47. Graves, M. C., M. C. Meidel, Y. C. Pan, M. Manneberg, H. W. Lahm & F. Gruninger-Leitch: Identification of a human immunodeficiency virus-1 protease cleavage site within the 66,000 Dalton subunit of reverse transcriptase. Biochem Biophys Res Commun. 168, 30-6 (1990)
48. Gotte, M., X. Li & M. A. Wainberg: HIV-1 reverse transcription: a brief overview focused on structure-function relationships among molecules involved in initiation of the reaction. Arch Biochem Biophys. 365, 199-210 (1999)
49. Kensch, O., B. A. Connolly, H. J. Steinhoff, A. McGregor, R. S. Goody & T. Restle: HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J. Biol. Chem. J. Biol. Chem. 275, 18271-8 (2000)
50. Kohlstaedt, L. A., J. Wang, J. M. Friedman, P. A. Rice & T. A. Steitz: Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256, 1783-90 (1992)
51. Spence, R. A., W. M. Kati, K. S. Anderson & K. A. Johnson: Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 267, 988-93 (1995)
52. Yazdanpanah, Y., D. Sissoko, M. Egger, Y. Mouton, M. Zwahlen & G. Chene: Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials. Brit. Med. J. 328, 249 (2004)
53. Shaw-Reid, C. A., V. Munshi, P. Graham, A. Wolfe, M. Witmer, R. Danzeisen, D. B. Olsen, S. S. Carroll, M. Embrey, J. S. Wai, M. D. Miller, J. L. Cole & D. J. Hazuda: Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-(5-(benzoylamino)thien-2-yl)-2,4-dioxobutanoic acid. J. Biol. Chem. 278, 2777-80 (2003)
54. Carr, A., Toxicity of antiretroviral therapy and implications for drug development. Nat Rev Drug Discov 2, 624-34 (2003).
55. Menendez-Arias, L.: Targeting HIV: antiretroviral therapy and development of drug resistance. Trends Pharmacol Sci 23, 381-8 (2002)
56. Little, S., S. Holte, J. Roury, E. Daar, M. Markowitz, A. Collier, R. Koup, J. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. Whitcomb, N. Hellmann & D. Richman: Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med 347, 385-394 (2002)
57. Yerly, S., L. Kaiser, E. Race, J. Bru, F. Clavel & L. Perrin: Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354, 729-733 (1999)
58. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance: Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. Brit. Med. J. 322, 1087-1088 (2001)
59. Phillips, A.: Will the drugs still work? Transmission of resistant HIV. Nat. Med 7, 993-994 (2001)
60. Blower, S., A. Aschenbach, H. Gershengorn & J. Kahn: Predicting the unpredictable: transmission of drug-resistant HIV. Nat. Med 7, 1016-1020 (2001)
61. Gonzales, M., R. Machekano & R. Shafer: Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis 184, 998-1006 (2001)
62. Gonzales, M., T. Wu, J. Taylor, I. Belitskaya, R. Kantor, D. Israelski, S. Chou, A. Zolopa, W. Fessel & R. Shafer: Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS 17, 791-799 (2003)
63. Lafeuillade, A. & J. C. Tardy: Stavudine in the face of cross-resistance between HIV-1 nucleoside reverse transcriptase inhibitors: a review. AIDS Rev. 5, 80-6 (2003)
64. Huang, H., R. Chopra, G. L. Verdine & S. C. Harrison: Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282, 1669-75 (1998)
65. Chamberlain, P. P., J. Ren, C. E. Nichols, L. Douglas, J. Lennerstrand, B. A. Larder, D. I. Stuart & D. K. Stammers: Crystal structures of Zidovudine- or Lamivudine-resistant human immunodeficiency virus type 1 reverse transcriptases containing mutations at codons 41, 184, and 215. J. Virol 76, 10015-9 (2002)
66. Ren, J., L. E. Bird, P. P. Chamberlain, G. B. Stewart-Jones, D. I. Stuart & D. K. Stammers: Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. U S A 99, 14410-5 (2002)
67. Ren, J., C. E. Nichols, P. P. Chamberlain, K. L. Weaver, S. A. Short & D. K. Stammers: Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors. J. Mol. Biol 336, 569-78 (2004)
68. Chen, H. & L. Gold: Selection of high-affinity RNA ligands to reverse transcriptase: inhibition of cDNA synthesis and RNase H activity. Biochemistry 33, 8746-56 (1994)
69. Chen, H., D. G. McBroom, Y. Q. Zhu, L. Gold & T. W. North: Inhibitory RNA ligand to reverse transcriptase from feline immunodeficiency virus. Biochemistry 35, 6923-30 (1996)
70. Schneider, D. J., J. Feigon, Z. Hostomsky & L. Gold: High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry 34, 9599-610 (1995)
71. Andreola, M. L., F. Pileur, C. Calmels, M. Ventura, L. Tarrago-Litvak, J. J. Toulme & S. Litvak: DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry 40, 10087-94 (2001)
72. Green, L., S. Waugh, J. P. Binkley, Z. Hostomska, Z. Hostomsky & C. Tuerk: Comprehensive chemical modification interference and nucleotide substitution analysis of an RNA pseudoknot inhibitor to HIV-1 reverse transcriptase. J. Mol. Biol. J. Mol. Biol. 247, 60-8 (1995)
73. Hannoush, R. N., S. Carriero, K. L. Min & M. J. Damha: Selective inhibition of HIV-1 reverse transcriptase (HIV-1 RT) RNase H by small RNA hairpins and dumbbells. Chembiochem 5, 527-33 (2004)
74. Jaeger, J., T. Restle & T. A. Steitz: The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor. Embo J 17, 4535-42 (1998)
75. Jacobo-Molina, A., J. Ding, R. G. Nanni, A. D. Clark, Jr., X. Lu, C. Tantillo, R. L. Williams, G. Kamer, A. L. Ferris, P. Clark, A. Hizi, S. H. Hughes & E. Arnold: Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 Å resolution shows bent DNA. Proc. Natl. Acad. Sci. U S A 90, 6320-4 (1993)
76. Sarafianos, S. G., K. Das, C. Tantillo, A. D. Clark, Jr., J. Ding, J. M. Whitcomb, P. L. Boyer, S. H. Hughes & E. Arnold: Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. Embo J 20, 1449-61.
77. Pileur, F., M. L. Andreola, E. Dausse, J. Michel, S. Moreau, H. Yamada, S. A. Gaidamakov, R. J. Crouch, J. J. Toulme & C. Cazenave: Selective inhibitory DNA aptamers of the human RNase H1. Nuc. Acids Res., 31, 5776-88 (2003)
78. de Soultrait, V. R., P. Y. Lozach, R. Altmeyer, L. Tarrago-Litvak, S. Litvak & M. L. Andreola: DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J. Mol. Biol., 324, 195-203 (2002)
79. Benedict, C. M., W. Pan, S. E. Loy & G. A. Clawson: Triple ribozyme-mediated down-regulation of the retinoblastoma gene. Carcinogenesis 19, 1223-30 (1998)
80. Chaloin, L., M. J. Lehmann, G. Sczakiel & T. Restle: Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nuc. Acids Res. 30, 4001-8 (2002)
81. Fisher, T. S., T. Darden & V. R. Prasad: Mutations proximal to the minor groove-binding track of human immunodeficiency virus type 1 reverse transcriptase differentially affect utilization of RNA versus DNA as template. J. Virol. 77, 5837-45 (2003)
82. Fisher, T. S., P. Joshi & V. R. Prasad: Mutations that confer resistance to template-analog inhibitors of human immunodeficiency virus (HIV) type 1 reverse transcriptase lead to severe defects in HIV replication. J. Virol., 76, 4068-72 (2002)
83. Witkin, E. M. & V. Roegner-Maniscalco: Overproduction of DnaE protein (alpha subunit of DNA polymerase III) restores viability in a conditionally inviable Escherichia coli strain deficient in DNA polymerase I. J Bacteriol 174, 4166-8 (1992)
84. Kim, B. & L. A. Loeb: Human immunodeficiency virus reverse transcriptase substitutes for DNA polymerase I in Escherichia coli. Proc. Natl. Acad. Sci. U S A 92, 684-8 (1995)
85. Kim, B., T. R. Hathaway & L. A. Loeb3A Human immunodeficiency virus reverse transcriptase. Functional mutants obtained by random mutagenesis coupled with genetic selection in Escherichia coli. J. Biol. Chem., 271, 4872-8 (1996)
86. Debouck, C.: The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 8, 153-64 (1992)
87. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. Dixon, E. M. Scolnick & I. S. Sigal: Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. U S A 85, 4686-90 (1988)
88. Peng, C., B. K. Ho, T. W. Chang & N. T. Chang: Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity. J. Virol. 63, 2550-6 (1989)
89. Adachi, A., N. Ono, H. Sakai, K. Ogawa, R. Shibata, T. Kiyomasu, H. Masuike & S. Ueda: Generation and characterization of the human immunodeficiency virus type 1 mutants. Arch Virol. 117, 45-58 (1991)
90. Tomasselli, A. G. & R. L. Heinrikson: Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim Biophys Acta 1477, 189-214 (2000)
91. Andre, P., M. Groettrup, P. Klenerman, R. de Giuli, B. L. Booth, Jr., V. Cerundolo, M. Bonneville, F. Jotereau, R. M. Zinkernagel & V. Lotteau: An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc. Natl. Acad. Sci. U S A 95, 13120-4 (1998)
92. Liang, J. S., O. Distler, D. A. Cooper, H. Jamil, R. J. Deckelbaum, H. N. Ginsberg & S. L. Sturley: HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7, 1327-31 (2001)
93. Blight, K. J., A. A. Kolykhalov & C. M. Rice: Efficient initiation of HCV RNA replication in cell culture. Science 290, 1972-4 (2000)
94. Bartenschlager, R.: Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov 1, 911-6.
95. Schroder, A. R., P. Shinn, H. Chen, C. Berry, J. R. Ecker & F. Bushman: HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521-9 (2002)
96. Wu, X., Y. Li, B. Crise & S. M. Burgess: Transcription start regions in the human genome are favored targets for MLV integration. Science 300, 1749-51 (2003)
97. Dyda, F., A. B. Hickman, T. M. Jenkins, A. Engelman, R. Craigie & D. R. Davies: Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 266, 1981-6 (1994)
98. Craigie, R.: HIV integrase, a brief overview from chemistry to therapeutics. J. Biol. Chem., 276, 23213-6 (2001)
99. Engelman, A., G. Englund, J. M. Orenstein, M. A. Martin & R. Craigie: Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J. Virol. 69, 2729-36 (1995)
100. Englund, G., T. S. Theodore, E. O. Freed, A. Engleman & M. A. Martin: Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J. Virol. 69, 3216-9 (1995)
101. Wiskerchen, M. & M. A. Muesing: Identification and characterization of a temperature-sensitive mutant of human immunodeficiency virus type 1 by alanine scanning mutagenesis of the integrase gene. J. Virol. 69, 597-601 (1995)
102. Cannon, P. M., E. D. Byles, S. M. Kingsman & A. J. Kingsman: Conserved sequences in the carboxyl terminus of integrase that are essential for human immunodeficiency virus type 1 replication. J. Virol. 70, 651-7 (1996)
103. Leavitt, A. D., G. Robles, N. Alesandro & H. E. Varmus: Human immunodeficiency virus type 1 integrase mutants retain in vitro integrase activity yet fail to integrate viral DNA efficiently during infection. J. Virol. 70, 721-8 (1996)
104. Nair, V.: HIV integrase as a target for antiviral chemotherapy. Rev Med Virol 12, 179-93 (2002)
105. Hazuda, D. J., P. Felock, M. Witmer, A. Wolfe, K. Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski, W. Schleif, C. Blau & M. D. Miller: Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646-50 (2000)
106. Allen, P., S. Worland & L. Gold: Isolation of high-affinity RNA ligands to HIV-1 integrase from a random pool. Virology 209, 327-36 (1995)
107. Rando, R. F., J. Ojwang, A. Elbaggari, G. R. Reyes, R. Tinder, M. S. McGrath & M. E. Hogan: Suppression of human immunodeficiency virus type 1 activity in vitro by oligonucleotides which form intramolecular tetrads. J. Biol. Chem. 270, 1754-60 (1995)
108. Mazumder, A., N. Neamati, J. O. Ojwang, S. Sunder, R. F. Rando & Y: Pommier, Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 35, 13762-71 (1996)
109. Ojwang, J. O., R. W. Buckheit, Y. Pommier, A. Mazumder, K. De Vreese, J. A. Este, D. Reymen, L. A. Pallansch, C. Lackman-Smith, T. L. Wallace, E. De Clercq, M. S. McGrath & R. F. Rando: T30177, an oligonucleotide stabilized by an intramolecular guanosine octet, is a potent inhibitor of laboratory strains and clinical isolates of human immunodeficiency virus type 1. Antimicrob Agents Chemother 39, 2426-35 (1995)
110. Fischer, U., J. Huber, W. C. Boelens, I. W. Mattaj & R. Luhrmann: The HIV-1 Rev activation domain is a nuclear export signal that accesses an export pathway used by specific cellular RNAs. Cell 82, 475-83 (1995)
111. Tuerk, C. & S. MacDougal-Waugh: In vitro evolution of functional nucleic acids: high-affinity RNA ligands of HIV-1 proteins. Gene 137, 33-9 (1993)
112. Giver, L., D. P. Bartel, M. L. Zapp, M. R. Green & A. D. Ellington: Selection and design of high-affinity RNA ligands for HIV-1 Rev. Gene 137, 19-24 (1993)
113. Malim, M. H., J. Hauber, S. Y. Le, J. V. Maizel & B. R. Cullen: The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338, 254-7 (1989)
114. Heguy, A.: Inhibition of the HIV Rev transactivator: A new target for therapeutic intervention. Front Biosci. 2, d283-97 (1997)
115. Bartel, D. P., M. L. Zapp, M. R. Green & J. W. Szostak: HIV-1 Rev regulation involves recognition of non-Watson-Crick base pairs in viral RNA. Cell 67, 529-36 (1991)
116. Battiste, J. L., H. Mao, N. S. Rao, R. Tan, D. R. Muhandiram, L. E. Kay, A. D. Frankel & J. R. Williamson: Alpha helix-RNA major groove recognition in an HIV-1 rev peptide-RRE RNA complex. Science 273, 1547-51 (1996)
117. Hung, L. W., E. L. Holbrook & S. R. Holbrook: The crystal structure of the Rev binding element of HIV-1 reveals novel base pairing and conformational variability. Proc. Natl. Acad. Sci. U S A, 97, 5107-12 (2000)
118. Peterson, R. D., D. P. Bartel, J. W. Szostak, S. J. Horvath & J. Feigon: 1H NMR studies of the high-affinity Rev binding site of the Rev responsive element of HIV-1 mRNA: base pairing in the core binding element. Biochemistry 33, 5357-66 (1994)
119. Ye, X., A. Gorin, A. D. Ellington & D. J. Patel: Deep penetration of an alpha-helix into a widened RNA major groove in the HIV-1 rev peptide-RNA aptamer complex. Nat Struct Biol 3, 1026-33 (1996)
120. Baskerville, S., M. Zapp & A. D. Ellington: Anti-Rex aptamers as mimics of the Rex-binding element. J. Virol. 73, 4962-71 (1999)
121. Baskerville, S., M. Zapp & A. D. Ellington: High-resolution mapping of the human T-cell leukemia virus type 1 Rex-binding element by in vitro selection. J. Virol. 69, 7559-69 (1995)
122. Ptak, R. G.: HIV-1 regulatory proteins: targets for novel drug development. Expert Opin Investig Drugs 11, 1099-115 (2002)
123. Lee, T. C., B. A. Sullenger, H. F. Gallardo, G. E. Ungers & E. Gilboa: Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells. New Biol 4, 66-74 (1992)
124. Lee, S. W., H. F. Gallardo, E. Gilboa & C. Smith: Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J. Virol., 68, 8254-64 (1994)
125. Bahner, I., K. Kearns, Q. L. Hao, E. M. Smogorzewska & D. B. Kohn: Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture. J. Virol., 70, 4352-60 (1996)
126. Yamada, O., G. Kraus, L. Luznik, M. Yu & F. Wong-Staal: A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. J. Virol., 70, 1596-601 (1996)
127. Gervaix, A., X. Li, G. Kraus & F. Wong-Staal: Multigene antiviral vectors inhibit diverse human immunodeficiency virus type 1 clades. J. Virol., 71, 3048-53 (1997)
128. Nakaya, T., S. Iwai, K. Fujinaga, Y. Sato, E. Otsuka & K. Ikuta: Decoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev protein. Antimicrob Agents Chemother 41, 319-25 (1997)
129. Fraisier, C., A. Irvine, C. Wrighton, R. Craig & E. Dzierzak: High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector. Gene Ther. 5, 1665-76 (1998)
130. Park, H., M. V. Davies, J. O. Langland, H. W. Chang, Y. S. Nam, J. Tartaglia, E. Paoletti, B. L. Jacobs, R. J. Kaufman & S. Venkatesan: TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc. Natl. Acad. Sci. U S A, 91, 4713-7 (1994)
131. Shukla, R. R., P. L. Kimmel & A. Kumar: Human immunodeficiency virus type 1 Rev-responsive element RNA binds to host cell-specific proteins. J. Virol. 68, 2224-9 (1994)
132. Powell, D. M., M. C. Amaral, J. Y. Wu, T. Maniatis & W. C. Greene: HIV Rev-dependent binding of SF2/ASF to the Rev response element: possible role in Rev-mediated inhibition of HIV RNA splicing. Proc. Natl. Acad. Sci. U S A 94, 973-8 (1997)
133. Symensma, T. L., L. Giver, M. Zapp, G. B. Takle & A. D. Ellington: RNA aptamers selected to bind human immunodeficiency virus type 1 Rev in vitro are Rev responsive in vivo. J. Virol. 70, 179-87 (1996)
134. Konopka, K., N. S. Lee, J. Rossi & N. Duzgunes: Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication. Gene 255, 235-44 (2000)
135. Rana, T. M. & K. T. Jeang, Biochemical and functional interactions between HIV-1 Tat protein and TAR RNA. Arch Biochem Biophys 365, 175-85 (1999)
136. Greene, W. C. & B. M. Peterlin: Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat. Med 8, 673-80 (2002)
137. Brigati, C., M. Giacca, D. M. Noonan & A. Albini: HIV Tat, its TARgets and the control of viral gene expression. FEMS Microbiol Lett, 220, 57-65 (2003)
138. Daelemans, D., A.-M. Vandamme & E. De Clercq: Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antiviral Chemistry & Chemotherapy 10, 1-14 (1999)
139. Yamamoto, R., K. Murakami, K. Taira & P. Kumar: Isolation and characterization of an RNA that binds with high affinity to Tat protein of HIV-1 from a completely random pool of RNA. Gene Therapy and Molecular Biology 1, 451-466 (1998)
140. Yamamoto, R., M. Katahira, S. Nishikawa, T. Baba, K. Taira & P. K. Kumar: A novel RNA motif that binds efficiently and specifically to the Tat protein of HIV and inhibits the trans-activation by Tat of transcription in vitro and in vivo. Genes Cells 5, 371-88 (2000)
141. Kawakami, J., H. Imanaka, Y. Yokota & N. Sugimoto: In vitro selection of aptamers that act with Zn2+. J Inorg Biochem 82, 197-206 (2000)
142. Yamamoto, R., T. Baba & P. K. Kumar: Molecular beacon aptamer fluoresces in the presence of Tat protein of HIV-1. Genes Cells 5, 389-96 (2000)
143. Sullenger, B. A., H. F. Gallardo, G. E. Ungers & E. Gilboa: Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication. Cell 63, 601-8 (1990)
144. Browning, C. M., L. Cagnon, P. D. Good, J. Rossi, D. R. Engelke & D. M. Markovitz: Potent inhibition of human immunodeficiency virus type 1 (HIV-1) gene expression and virus production by an HIV-2 tat activation-response RNA decoy. J. Virol., 73, 5191-5 (1999)
145. Michienzi, A., S. Li, J. A. Zaia & J. J. Rossi: A nucleolar TAR decoy inhibitor of HIV-1 replication. Proc. Natl. Acad. Sci. U S A 99, 14047-52 (2002)
146. Li, M. J., G. Bauer, A. Michienzi, J. K. Yee, N. S. Lee, J. Kim, S. Li, D. Castanotto, J. Zaia & J. J. Rossi: Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. Mol Ther 8, 196-206 (2003)
147. Carpick, B. W., V. Graziano, D. Schneider, R. K. Maitra, X. Lee & B. R. Williams: Characterization of the solution complex between the interferon-induced, double-stranded RNA-activated protein kinase and HIV-I trans-activating region RNA. J. Biol. Chem. 272, 9510-6.
148. Gatignol, A., A. Buckler-White, B. Berkhout & K. T. Jeang: Characterization of a human TAR RNA-binding protein that activates the HIV-1 LTR. Science 251, 1597-600 (1991)
149. Gatignol, A., C. Buckler & K. T. Jeang: Relatedness of an RNA-binding motif in human immunodeficiency virus type 1 TAR RNA-binding protein TRBP to human P1/dsI kinase and Drosophila staufen. Mol Cell Biol 13, 2193-202 (1993)
150. Chepenik, L. G., A. P. Tretiakova, C. P. Krachmarov, E. M. Johnson & K. Khalili: The single-stranded DNA binding protein, Pur-alpha, binds HIV-1 TAR RNA and activates HIV-1 transcription. Gene 210, 37-44 (1998)
151. Wu-Baer, F., W. S. Lane & R. B. Gaynor: The cellular factor TRP-185 regulates RNA polymerase II binding to HIV-1 TAR RNA. Embo J 14, 5995-6009 (1995)
152. Wu-Baer, F., W. S. Lane & R. B. Gaynor: Identification of a group of cellular cofactors that stimulate the binding of RNA polymerase II and TRP-185 to human immunodeficiency virus 1 TAR RNA. J. Biol. Chem. 271, 4201-8 (1996)
153. Hart, C. E., M. J. Saltrelli, J. C. Galphin & G. Schochetman: A human chromosome 12-associated 83-kilodalton cellular protein specifically binds to the loop region of human immunodeficiency virus type 1 trans-activation response element RNA. J. Virol., 69, 6593-9 (1995)
154. Rothblum, C. J., J. Jackman, J. Mikovits, R. R. Shukla & A. Kumar: Interaction of nuclear protein p 140 with human immunodeficiency virus type 1 TAR RNA in mitogen-activated primary human T lymphocytes. J. Virol. 69, 5156-63 (1995)
155. Sullenger, B. A., H. F. Gallardo, G. E. Ungers & E. Gilboa: Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. J. Virol. 65, 6811-6 (1991)
156. Boiziau, C., E. Dausse, L. Yurchenko & J. J. Toulme, DNA aptamers selected against the HIV-1 trans-activation-responsive RNA element form RNA-DNA kissing complexes. J. Biol. Chem. 274, 12730-7 (1999)
157. Duconge, F. & J. J. Toulme: In vitro selection identifies key determinants for loop-loop interactions: RNA aptamers selective for the TAR RNA element of HIV-1. RNA 5, 1605-14 (1999)
158. Cho, B., D. C. Taylor, H. B. Nicholas, Jr.20& F. J. Schmidt: Interacting RNA species identified by combinatorial selection. Bioorg Med. Chem 5, 1107-13 (1997)
159. Darfeuille, F., A. Arzumanov, M. J. Gait, C. Di Primo & J. J. Toulme: 2′-O-methyl-RNA hairpins generate loop-loop complexes and selectively inhibit HIV-1 Tat-mediated transcription. Biochemistry 41, 12186-92 (2002)
160. Darfeuille, F., A. Arzumanov, S. Gryaznov, M. J. Gait, C. Di Primo & J. J. Toulme: Loop-loop interaction of HIV-1 TAR RNA with N3′→ P5′ deoxyphosphoramidate aptamers inhibits in vitro Tat-mediated transcription. Proc. Natl. Acad. Sci. U S A 99, 9709-14 (2002)
161. Freed, E. O.: HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251, 1-15 (1998)
162. Javanbakht, H., R. Halwani, S. Cen, J. Saadatmand, K. Musier-Forsyth, H. Gottlinger & L. Kleiman: The interaction between HIV-1 Gag and human lysyl-tRNA synthetase during viral assembly. J. Biol. Chem. 278, 27644-51 (2003)
163. Halwani, R., S. Cen, H. Javanbakht, J. Saadatmand, S. Kim, K. Shiba & L. Kleiman: Cellular distribution of Lysyl-tRNA synthetase and its interaction with Gag during human immunodeficiency virus type 1 assembly. J. Virol. 78, 7553-64 (2004)
164. Weiss, S., B. Konig, Y. Morikawa & I. Jones: Recombinant HIV-1 nucleocapsid protein p15 produced as a fusion protein with glutathione S-transferase in Escherichia coli mediates dimerization and enhances reverse transcription of retroviral RNA. Gene 121, 203-12 (1992)
165. Lapadat-Tapolsky, M., C. Pernelle, C. Borie & J. L. Darlix: Analysis of the nucleic acid annealing activities of nucleocapsid protein from HIV-1. Nuc. Acids Res. 23, 2434-41 (1995)
166. Tisne, C., B. P. Roques & F. Dardel: Specific recognition of primer tRNA(Lys)(3) by HIV-1 nucleocapsid protein: involvement of the zinc fingers and the N-terminal basic extension. Biochimie 85, 557-61 (2003)
167. Allain, B., M. Lapadat-Tapolsky, C. Berlioz & J. L. Darlix: Transactivation of the minus-strand DNA transfer by nucleocapsid protein during reverse transcription of the retroviral genome. Embo J 13, 973-81 (1994)
168. Hong, M. K., E. J. Harbron, D. B. O'Connor, J. Guo, P. F. Barbara, J. G. Levin & K. Musier-Forsyth: Nucleic acid conformational changes essential for HIV-1 nucleocapsid protein-mediated inhibition of self-priming in minus-strand transfer. J. Mol. Biol. 325, 1-10 (2003)
169. Lee, N., R. J. Gorelick & K. Musier-Forsyth: Zinc finger-dependent HIV-1 nucleocapsid protein-TAR RNA interactions. Nuc. Acids Res. 31, 4847-55 (2003)
170. Gorelick, R. J., S. M. Nigida, Jr., J. W. Bess, Jr., L. O. Arthur, L. E. Henderson & A. Rein: Noninfectious human immunodeficiency virus type 1 mutants deficient in genomic RNA. J. Virol 64, 3207-11 (1990)
171. Gorelick, R. J., T. D. Gagliardi, W. J. Bosche, T. A. Wiltrout, L. V. Coren, D. J. Chabot, J. D. Lifson, L. E. Henderson & L. O. Arthur: Strict conservation of the retroviral nucleocapsid protein zinc finger is strongly influenced by its role in viral infection processes: characterization of HIV-1 particles containing mutant nucleocapsid zinc-coordinating sequences. Virology 256, 92-104 (1999)
172. Allen, P., B. Collins, D. Brown, Z. Hostomsky & L. Gold: A specific RNA structural motif mediates high affinity binding by the HIV-1 nucleocapsid protein (NCp7) Virology 225, 306-15 (1996)
173. Berglund, J. A., B. Charpentier & M. Rosbash, A high affinity binding site for the HIV-1 nucleocapsid protein. Nuc. Acids Res., 1997. 25(5): p. 1042-9.
174. Lochrie, M. A., S. Waugh, D. G. Pratt, Jr., J. Clever, T. G. Parslow & B. Polisky: In vitro selection of RNAs that bind to the human immunodeficiency virus type-1 gag polyprotein. Nuc. Acids Res. 25, 2902-10 (1997)
175. Kim, S. J., M. Y. Kim, J. H. Lee, J. C. You & S. Jeong: Selection and stabilization of the RNA aptamers against the human immunodeficiency virus type-1 nucleocapsid protein. Biochem Biophys Res Commun 291, 925-31 (2002)
176. Dorman, N. M. & A. M. Lever: Investigation of RNA transcripts containing HIV-1 packaging signal sequences as HIV-1 antivirals: generation of cell lines resistant to HIV-1. Gene Ther 8, 157-65 (2001)
177. Kim, M. Y. & S. Jeong: Inhibition of the functions of the nucleocapsid protein of human immunodeficiency virus-1 by an RNA aptamer. Biochem Biophys Res Commun 320, 1181-6 (2004)
178. Kilby, J. M., S. Hopkins, T. M. Venetta, B. DiMassimo, G. A. Cloud, J. Y. Lee, L. Alldredge, E. Hunter, D. Lambert, D. Bolognesi, T. Matthews, M. R. Johnson, M. A. Nowak, G. M. Shaw & M. S. Saag: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4, 1302-7 (1998)
179. Lalezari, J. P., E. DeJesus, D. W. Northfelt, G. Richmond, P. Wolfe, R. Haubrich, D. Henry, W. Powderly, S. Becker, M. Thompson, F. Valentine, D. Wright, M. Carlson, S. Riddler, F. F. Haas, R. DeMasi, P. R. Sista, M. Salgo & J. Delehanty: A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults. Antivir Ther 8, 279-87 (2003)
180. Wild, C. T., D. C. Shugars, T. K. Greenwell, C. B. McDanal & T. J. Matthews: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc. Natl. Acad. Sci. U S A 91, 9770-4 (1994)
181. Rimsky, L. T., D. C. Shugars & T. J. Matthews: Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J. Virol. 72, 986-93 (1998)
182. Khati, M., M. Schuman, J. Ibrahim, Q. Sattentau, S. Gordon & W. James: Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2′F-RNA aptamers. J. Virol. 77, 12692-8 (2003)
183. Sayer, N., J. Ibrahim, K. Turner, A. Tahiri-Alaoui & W. James: Structural characterization of a 2′F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120. Biochem Biophys Res Commun 293, 924-31 (2002)
184. Smith, D., B. D. Collins, J. Heil & T. H. Koch: Sensitivity and specificity of photoaptamer probes. Mol Cell Proteomics 2, 11-8 (2003)
185. Golden, M. C., B. D. Collins, M. C. Willis & T. H. Koch, Diagnostic potential of PhotoSELEX-evolved ssDNA aptamers. J Biotechnol 81, 167-78 (2000)
186. Sheeny, A. M., N. C. Gaddis, J. D. Choi & M. H. Malim: Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418, 646-50 (2002)
187. Kao, S., M. A. Khan, E. Miyagi, R. Plishka, A. Buckler-White & K. Strebel: The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J. Virol. 77, 11398-407 (2003)
188. Spira, S., M. A. Wainberg, H. Loemba, D. Turner & B. G. Brenner: Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother 51, 229-40 (2003)
189. White, R., C. Rusconi, E. Scardino, A. Wolberg, J. Lawson, M. Hoffman & B. Sullenger: Generation of species cross-reactive aptamers using "toggle" SELEX. Mol Ther 4, 567-73 (2001)
190. Morris, K. V. & J. J. Rossi: Anti-HIV-1 gene expressing lentiviral vectors as an adjunctive therapy for HIV-1 infection. Curr HIV Res 2, 185-91 (2004)
191. Wyatt, J. R., T. A. Vickers, J. L. Roberson, R. W. Buckheit, Jr., T. Klimkait, E. DeBaets, P. W. Davis, B. Rayner, J. L. Imbach & D. J. Ecker: Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion. Proc. Natl. Acad. Sci. U S A 91, 1356-60.
192. Bai, J., N. Banda, N. S. Lee, J. Rossi & R. Akkina: RNA-Based Anti-HIV-1 Gene Therapeutic Constructs in SCID-hu Mouse Model. Mol Ther 6, 770-82 (2002)